Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12

F. Heitz, P. Harter, E. Åvail-Lundqvist, A. Reuss, P. Pautier, G. Cormio, N. Colombo, A. Reinthaller, I. Vergote, A. Poveda, P. B. Ottevanger, L. C. Hanker, A. Leminen, J. Alexandre, U. Canzler, J. Sehouli, J. Herrstedt, B. Fiane, M. Merger, A. du Bois

Research output: Contribution to journalArticleScientificpeer-review

Original languageEnglish
JournalGynecologic Oncology
Volume152
Issue number2
Pages (from-to)235-242
Number of pages8
ISSN0090-8258
DOIs
Publication statusPublished - Feb 2019
MoE publication typeA1 Journal article-refereed

Fields of Science

  • Advanced ovarian cancer
  • Debulking surgery
  • Pre-chemotherapy imaging
  • Prognosis
  • EPITHELIAL OVARIAN
  • CYTOREDUCTIVE SURGERY
  • COMPUTED-TOMOGRAPHY
  • POSTOPERATIVE CT
  • CHEMOTHERAPY
  • BEVACIZUMAB
  • CARCINOMA
  • INITIATION
  • INTERVAL
  • THERAPY
  • 3123 Gynaecology and paediatrics

Cite this